Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Argos Therapeutics

The problem with clinical trials (and how virtual insight-gathering can help)

While still the gold standard of research, clinical trials are often riddled with issues that limit their applicability to broader populations or delay market access.

Impetus Digital

- PMLiVE

UK government and NIHR accelerate plans to improve clinical research delivery

The government has created a focused plan for action to transform UK clinical research

- PMLiVE

Innovative Trials at the 2023 Lloyds Bank British Business Excellence Awards

Innovative Trials achievements recognized at the Lloyds Bank British Business Excellence Awards

Innovative Trials

- PMLiVE

AstraZeneca gains rights to Usynova’s KRAS inhibitor in deal worth almost $420m

There are currently no approved drugs specifically targeting the KRAS G12D mutation

- PMLiVE

Boehringer Ingelheim to acquire T3 Pharmaceuticals in deal worth over $500m

The acquisition marks a significant boost to Boehringer’s immuno-oncology portfolio

- PMLiVE

ABPI report shows improvement in UK industry clinical trial performance

The data showed a 15% increase in annual recruitment to UK industry clinical trials

EU flag

EC approves pharmaand’s Rubraca as advanced ovarian cancer maintenance treatment

An estimated 66,000 new cases of ovarian cancer are diagnosed in Europe each year

- PMLiVE

Pfizer and Astellas’ Xtandi approved by FDA for earlier prostate cancer indication

Xtandi is the first androgen receptor signalling inhibitor approved for this patient population

- PMLiVE

Merck receives FDA approval for Keytruda combination in gastric cancer

An estimated 26,500 people in the US will be diagnosed with gastric cancer in 2023

- PMLiVE

Bristol Myers Squibb’s lung cancer drug Augtyro receives FDA approval

The drug was added to BMS’ portfolio last year through its $4.1bn acquisition of Turning Point

- PMLiVE

Novartis gains global rights to Legend’s CAR-T cell therapies in deal worth over $1bn

Novartis can apply its T-Charge platform to the manufacturing process of the therapies

- PMLiVE

New genetic variants linked to prostate cancer in men with African ancestry

A dataset was compiled for the research containing DNA from over 944,000 men

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links